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Abstract Dendritic cells (DCs) are known to modulate immune
response by activating e¡ector cells of both the innate and the
adaptive immune system. In the present study, we demonstrate
that co-culture of DCs with paraformaldehyde-¢xed tumor cells
augments the secretion of interleukin (IL)-12 by DCs and these
activated DCs upon co-culture with naive NK cells enhance the
cytolytic activity of NK cells against NK-sensitive target YAC-
1. Similarly, DCs isolated from tumor-bearing animals also
activated NK cells in vitro. For e⁄cient activation of NK cells,
the ratio of activated DCs to NK cells is crucial. Addition of
anti-IL-12 antibody to the culture system completely abolished
activation of NK cells by DCs, suggesting that IL-12 secreted
by DCs is an essential factor in NK cell activation. Adoptive
transfer of DCs isolated from tumor-bearing animals into nor-
mal rats also induced activation of NK cells in normal animals.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Dendritic cells (DCs) are unique antigen-presenting cells [1],
as they can both initiate and modulate immune response.
Even a small number of DCs and a low level of antigen can
elicit a strong immune response by activating naive T cells, B
cells [2] and NK cells [3] and also play a critical role in the
induction of peripheral immunological tolerance [4]. DCs
have been shown to augment the cytotoxic function of NK
cells [5,6]. Recent ¢ndings that DCs produce interleukin (IL)-2
after microbial challenge suggest this to be the mechanism by
which DCs link innate and adaptive immunity [7]. Recently
DCs have been shown to produce interferon-Q (IFN-Q) [8],
which is essential for both innate and adaptive immunity.
Moreover, T-bet (a transcription factor) is required for the
optimal production of IFN-Q by both CD8Kþ and CD8K3
DCs [9]. Stimuli inducing maturation of DCs include micro-
bial products and interaction with activated T lymphocytes.
Mature DCs upregulate co-stimulatory molecules, secrete cy-
tokines and migrate to the secondary lymphoid tissues where
they trigger speci¢c e¡ector cell response.
NK cells are the e¡ector cells of innate immunity and me-
diate spontaneous cytotoxicity against a broad range of tar-
gets including major histocompatibility complex (MHC) class
I-negative tumor cells [10]. The mechanism of NK cell-medi-
ated oncolysis involves a complex array of events. The cyto-
lytic activity of NK cells is augmented by IL-2 and to a lesser
extent by other cytokines including IL-12 and IFN-Q [11].
Recently DCs engineered to express IL-12 have been shown
to activate NK cells [12].
AK-5 is a highly immunogenic rat histiocytic tumor, which
regresses spontaneously in syngeneic animals when trans-
planted s.c., whereas it kills 100% of animals when trans-
planted i.p. [13]. The death of AK-5 cells is achieved through
necrosis and apoptosis mediated by NK cells, macrophages
and B cells [14,15]. NK cells have been demonstrated to be
the major e¡ector cells and require priming/activation before
they can participate in the induction of death in AK-5 cells.
In this study, we have studied the role of DCs in AK-5
regression. We observed activation of DCs upon co-culture
with ¢xed tumor cells, which in turn activated NK cells. Sim-
ilar observations were also made when adoptively transferred
mature DCs isolated from 8th day tumor-bearing animals
were injected into naive animals, thereby suggesting an impor-
tant role for mature DCs in the activation of NK cell e¡ector
function.
2. Materials and methods
2.1. Animals and tumors
AK-5 tumors were maintained as ascites in 6^8 week old Wistar
rats obtained from the inbred colony of this laboratory by injecting
5U106 AK-5 cells i.p. Solid AK-5 tumors were obtained by injecting
5U106 AK-5 cells s.c. in 6 week old rats. The murine lymphoma cell
line YAC-1 was maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin
and 50 Wg/ml streptomycin.
2.2. Antibodies
Monoclonal antibody (mAb) OX-6 (MHC-II) was from Pharmin-
gen, USA. Hybridoma OX-62 (KO-integrin) was kindly provided by
Dr. M.J. Puklavec and B7.2 (CD86) by Dr. Vijay Kuchroo. Anti-
mouse IL-12 (c17.15, p40 subunit) and anti-mouse IFN-Q (XMG1.2)
were kindly provided by Dr. G. Trinchieri and Dr. R.L. Co¡man
respectively. Anti-mouse Ig Alexa 568 was from Molecular Probes
and anti-mouse Ig £uorescein isothiocyanate (FITC) was purchased
from Amersham, UK.
2.3. Isolation of DCs and NK cells from spleen
Spleens from normal or di¡erent day (s.c.) tumor-bearing rats were
removed aseptically and teased in RPMI 1640 medium. Mononuclear
cells were obtained after fractionation on Ficoll-Hypaque density gra-
dient. DCs and NK cells were isolated using magnetic beads (Dynal,
Chantilly, VA, USA) coated with mAb OX-62 and anti-CD161 mAb
respectively. For further DC puri¢cation, cells were plated in RPMI
1640 containing 10% FCS overnight at 37‡C in a CO2 incubator and
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the non-adherent cells were removed. DCs isolated by this procedure
were s 90% pure.
2.4. Co-culture of DCs with tumor cells
AK-5 tumor cells were washed with phosphate-bu¡ered saline
(PBS) and ¢xed in 3% paraformaldehyde for 30 min at room temper-
ature. DCs (5U105/ml) were co-cultured with ¢xed AK-5 cells at
di¡erent DC to AK-5 cell ratios in RPMI 1640 medium supplemented
with 10% heat-inactivated FCS for 18 h.
2.5. Co-culture of DCs with NK cells
DCs isolated from 8th day tumor-bearing rats or previously co-
cultured for 18 h with ¢xed tumor cells (50:1) or from normal rats
were further co-cultured with naive NK cells at di¡erent ratios (3:1 to
0.5:1). After 18 h incubation, NK cells were separated on magnetic
beads and tested for their cytolytic activity against YAC-1 cells.
2.6. RNA isolation and reverse transcription polymerase chain reaction
(RT-PCR)
Total cellular RNA was isolated using Trizol reagent (Gibco BRL).
Single-stranded cDNA was prepared in a 20 Wl reaction volume using
500 ng of oligo(dT)12^18 primer, 15 units of AMV reverse transcrip-
tase (Promega) and 2 Wg of RNA. 50 Wl PCR reactions containing 50
mM KCl, 1.5 mM MgCl2, 10 mM Tris^HCl pH 9.2, 200 mM of each
dNTP, 0.1% Triton X-100, 200 nM of each primer, 1.25 U Taq poly-
merase and 2 Wl of cDNA solution were set up. Primers speci¢c for
cytokines IL-2, IL-12 and IFN-Q were used along with GAPDH prim-
ers. The PCR products were con¢rmed after hybridization with IL-2-,
IL-12- or IFN-Q-speci¢c cDNA probes.
2.7. MTT assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay used in measuring antitumor cell-mediated cytotoxicity
was modi¢ed for adherent e¡ector cells [16]. Brie£y, experimental
wells contained both DCs and tumor cells (E:T= 50:1) and control
wells included DCs or tumor cells alone. Cells were cultured for 18 h,
followed by incubation with MTT for 2 h at 37‡C. The generated
formazan was read at 590 nm and the percentage cytotoxicity was
calculated.
2.8. Immuno£uorescence and £ow cytometry
DCs isolated from normal or tumor-bearing animals were ¢xed in
3% paraformaldehyde at room temperature for 30 min and treated
with primary antibodies against OX-62, OX-41, OX-6 and B7-2 for 1 h
at room temperature. The secondary antibodies used were FITC or
Alexa-568-conjugated anti-mouse Ig. The cells were analyzed by £ow
cytometry.
2.9. Cytotoxicity assay
Cytotoxicity assay was performed by a 4 h 51Cr release assay. Ac-
tivated NK cells were isolated from the DC-NK co-culture experiment
or NK cells from mature DC adoptively transferred animals and were
incubated with 51Cr-labelled YAC-1 cells (E:T= 25:1) for 4 h. 51Cr
released in the medium was counted in a Packard Gamma Counter
and the percentage cytotoxicity was calculated.
2.10. Enzyme-linked immuno¢ltration assay (ELIFA)
The cytokine levels in the co-culture supernatants were quanti¢ed
by ELIFA (Pierce, USA). The culture supernatant was ¢ltered
through a nitrocellulose membrane, allowing the protein to bind to
the membrane. The membrane was blocked with PBS-bovine serum
albumin solution followed by treatment with primary antibody for IL-
12 or IFN-Q and after washing it was treated with horseradish per-
oxidase-conjugated anti-rat Ig antibody. The membrane was washed
and the signal bound to the membrane was developed for peroxidase.
2.11. Adoptive transfer experiments
For adoptive transfer of mature DCs (from 8th day s.c. tumor-
bearing rat spleens), two groups of normal Wistar rats were injected
i.p. twice each week for 3 weeks (2U106 DCs/dose/animal). The con-
trol group received immature DCs obtained from naive Wistar rats.
One group of rats was killed after the scheduled dose of i.p. injections
and spleens were removed to isolate NK cells which were checked
further for cytotoxicity against YAC-1 cells. In the other group of
animals, AK-5 tumor was injected i.p. (1U106/rat) and the animals
were monitored for tumor growth (ascites).
2.12. Statistical analysis
Student’s t-test was performed to analyze the signi¢cance of the
di¡erence between control and experimental groups. Di¡erences
were considered signi¢cant at P6 0.01.
3. Results
3.1. Activation of DCs by ¢xed tumor cells
DCs isolated following the procedure described above were
s 90% pure as assessed by dendritic morphology and pheno-
typic markers such as KO-integrin (OX-62) (Fig. 1A) and up-
regulation of MHC class II (OX-6) and CD86 (B7-2) upon
stimulation leading to maturation. To investigate whether
¢xed tumor cells could activate DCs upon co-culture, several
parameters of DC activation were studied. We tested the abil-
ity of ¢xed AK-5 cells to upregulate DC maturation markers,
viz., secretion of IL-12 and IFN-Q and upregulation of the
surface expression of MHC-II and CD86.
DCs were incubated with ¢xed AK-5 cells at di¡erent ratios
(DC:AK-5, 100:1^1:1) for 18 h before analyzing for the
secretion of IL-12 and IFN-Q (Fig. 1B) or for phenotype
evaluation of MHC-II and CD86 (Fig. 1C). Di¡erences in
IL-12 and IFN-Q secretion between DCs incubated with or
without ¢xed AK-5 cells were signi¢cant. In addition, ¢xed
AK-5 tumor cells induced DC activation in a dose-dependent
manner (Fig. 1B). The augmentation in the activation of DCs
following exposure to ¢xed AK-5 cells was not due to
the binding of mAb OX-62, because the control DCs were
also isolated using the same procedure. In addition ¢xed
AK-5 cells did not produce either IL-12 or IFN-Q (data not
shown).
DCs isolated from di¡erent day AK-5 tumor-bearing rats
showed expression of several markers as analyzed by RT-PCR
for cytokines IL-2, IL-12 and IFN-Q (Fig. 2). DCs from 8th
day tumor-bearing rats were mature as analyzed by the
mRNA transcript levels of IL-12 (whereas IL-2 transcripts
were present at very low levels). IFN-Q transcripts were highly
expressed in all the samples of DCs collected from di¡erent
day tumor-bearing rats. They also showed upregulation of
MHC-II and CD86 expression (Fig. 1C). For subsequent ex-
periments, like NK cell activation assays and adoptive trans-
fer experiments, DCs isolated from 8th day tumor-bearing
rats were used.
3.2. Immature but not mature DCs induced death in tumor cells
To rule out the possibility that mature DCs directly induce
death signal in tumor cells, AK-5 tumor cells were co-cultured
with immature DCs or mature DCs isolated from di¡erent
day (s.c.) tumor-bearing rat spleens (E:T= 50:1). After 18 h
incubation, cell viability was checked by the MTT assay. We
observed signi¢cantly higher apoptotic cell death in tumor
cells co-cultured with immature DCs, whereas the apoptotic
potential of DCs decreased gradually with maturation after
tumor transplantation (Fig. 3).
3.3. Mature DCs activate resting NK cells
Mature DCs obtained either from 8th day (s.c.) tumor-
bearing rat spleens or after co-culture with ¢xed AK-5 cells
were able to activate resting NK cells. Activation of NK cells
was checked after prior co-culture with mature DCs at di¡er-
ent ratios (3:1 to 0.5:1) for 18 h or naive NK cells for in-
duction of cytotoxicity against YAC-1 cells. NK cell cytotox-
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icity was highly augmented after an 18 h co-culture with ma-
ture DCs (Fig. 4).
3.4. Role of IL-12 in NK cell activation
Mature DCs secrete various cytokines that are involved in
activating NK cells. IL-12 and IFN-Q are NK cell stimulatory
cytokines, secreted during tumor development. We investi-
gated the role of IL-12 in DC-mediated NK cell activation.
Addition of neutralizing anti-IL-12 mAb to NK-DC co-cul-
ture experiments did block activation of NK cell cytotoxicity
(Fig. 5A). Inhibition of NK cell activity by anti-IL-12 anti-
body was signi¢cant (P6 0.001) as compared to activated NK
Fig. 1. A: DCs were isolated from rat spleens by positive selection using mAb OX-62 conjugated to magnetic beads. Panel 1, secondary anti-
body control; panel 2, OX-62-positive cells. B: Cytokine secretion by DCs after co-culture with ¢xed AK-5 cells. DCs (2U105) were incubated
with ¢xed AK-5 cells at di¡erent ratios for 18 h. IL-12 and IFN-Q levels in the supernatants were assayed by ELIFA. The levels shown are
meanSS.D. from three di¡erent experiments. C: Upregulation of MHC-II (OX-6) and CD86 (B7.2) in activated DCs after co-culture with
¢xed AK-5 cells for 18 h or DCs isolated from 8th day (s.c.) tumor-bearing rat spleens. Panel 1 shows control DCs, panel 2 shows DCs co-cul-
tured with ¢xed AK-5 cells and panel 3 shows DCs from tumor-bearing animals.
FEBS 28052 3-2-04
R.S. Alli, A. Khar/FEBS Letters 559 (2004) 71^76 73
cells by mature DCs. However, culture supernatants from
mature DC alone did not activate NK cells (data not shown),
suggesting that in addition to the cytokines secreted by DCs,
cell-to-cell contact may also be essential for activation.
3.5. NK cell activation by mature DCs in vivo
In order to study activation of NK cells by DCs in vivo, we
adoptively transferred mature or immature DCs obtained
from 8th day tumor-bearing or naive rats respectively. NK
cells obtained from DC-injected animals showed augmented
cytotoxicity against YAC-1 cells as compared to NK cells
obtained from control groups (Fig. 5B). Another set of ani-
mals that had received DC injections were challenged with
AK-5 cells i.p., monitored for tumor growth and mortality.
Although a considerable delay in tumor growth was observed,
none of the DC-injected animals survived (data not shown).
4. Discussion
This study demonstrates the activation of DCs after their
interaction with ¢xed tumor cells and in turn induction of
lytic function by NK cells and the requirement for cell-se-
creted accessory signals for the augmentation of the lytic func-
tion. It also demonstrates that adoptively transferred mature
DCs are able to activate NK cells for their cytotoxic potential
against the tumor. NK cells have been shown to be the e¡ec-
tor cells during AK-5 tumor regression [17].
A variety of factors can induce maturation/activation fol-
lowing antigen uptake and processing within DCs, including
whole bacteria or bacterial-derived antigens (e.g. lipopolysac-
charide (LPS)), in£ammatory cytokines (tumor necrosis fac-
tor-K, IL-1L, IL-6 and prostaglandin E2), ligation of select cell
surface receptors (e.g. CD40), viral products (e.g. double-
stranded RNA), tumor products (heat shock proteins, tu-
mor-associated antigens) etc. [17]. DC maturation is a process
where MHC and co-stimulatory molecules are upregulated
(e.g. CD80, CD86, CD40, OX-40-L and LBB1L). Simulta-
neously, they become primed to synthesize cytokines (IL-12,
IL-15 and IL-18) essential for the development of the innate
and the adaptive immune system [18].
In this study we have shown activation of immature DCs by
paraformaldehyde-¢xed tumor cells. Recently we have ob-
served NKR-P2/NKG2D expression on DCs (unpublished
observations), which may be interacting with its ligand on
¢xed AK-5 tumor cells thereby inducing activation of DCs.
Fig. 2. Expression of transcripts for IL-2, IL-12, IFN-Q cDNAs
were prepared from DCs obtained from (1) naive rats, (2) 8th day
tumor-bearing rats, and (3) 16th day tumor-bearing rats. GAPDH
is shown as loading control. The results shown are representative of
three similar experiments.
Fig. 3. Induction of apoptosis in AK-5 cells by immature and ma-
ture DCs isolated from di¡erent day (s.c.) tumor-bearing rat
spleens. The results shown are representative of three similar experi-
ments. *P6 0.01, **P6 0.001 with respect to immature DC control.
Fig. 4. A: Activation of naive NK cells by mature DCs isolated
from 8th day (s.c.) tumor-bearing rat spleens. NK cells and DCs
were co-cultured for 18 h at di¡erent ratios. NK cell cytotoxicity
was measured against YAC-1 target cells. The results shown are
representative of three similar experiments. *P6 0.001 with respect
to naive NK cell control. B: Activation of naive NK cells by preac-
tivated DCs (¢xed AK-5 cells co-cultured with DCs; DC:AK-
5= 50:1). NK cells and DCs were co-cultured for 18 h at di¡erent
ratios. Activation of NK cells was assayed by measuring cytotoxic-
ity against YAC-1 cells. *P6 0.001.
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The activated DCs secreted increased amounts of IL-12 and
expressed MHC class II and CD86 co-stimulatory molecules
(Fig. 1), which are the hallmark of DC maturation. DCs iso-
lated from tumor-bearing rats also showed high transcripts
for genes encoding IL-12 and IFN-Q (Fig. 2), in addition to
the expression of maturation markers like MHC-II and CD86
(Fig. 1C). Microorganisms or microbial products only seem to
induce the transcription of the gene encoding IL-2 in DCs [7].
Recent studies have established DCs as an important source
of IFN-Q. After a 72 h stimulation with IL-12 and IL-18, DCs
secreted substantial amounts of IFN-Q. T-bet in£uenced the
generation of type I immunity not only by controlling Th1
lineage commitment in the adaptive immune system but also
by directly in£uencing the transcription of IFN-Q gene in DCs
[9].
Immature DCs have been shown to be more e¡ective in
mediating tumor cell apoptosis than mature DCs, inducing
mitochondrial damage initially followed by DNA fragmenta-
tion [16]. It is known that immature, but not mature DCs
readily ingest apoptotic bodies and carry out antigen pre-
sentation. We tested the oncolytic activity of mature DCs
isolated from di¡erent day tumor-bearing rats and compared
it with that of immature DCs in MTT and 18 h 51Cr release
assays. Only in the MTT assay could we see a signi¢cant
di¡erence in the ability to induce death signals in tumor cells
(Fig. 3) by immature DCs; however, in the 51Cr release assay,
we were unable to detect cell death (data not shown) suggest-
ing that DCs may ¢rst induce mitochondrial damage and may
require a longer period of acquaintance with tumor cells for
DNA damage to occur. Maturation of DCs is known to be
accompanied by their multiple phenotypic and functional
changes including that of antigen-presenting activities and a
signi¢cant decrease of their tumoricidal function.
Previous reports in murine and human models demon-
strated that DCs were able to activate NK cells which in
turn retarded the growth of experimental tumors [3,19,20].
In the presence of a maturation stimulus DCs activated NK
cells that in turn strongly enhanced DC maturation. However,
the requirement for direct NK-DC contact, presence of solu-
ble factors and DC maturation varied in the di¡erent studies.
Fresh NK cells were activated as indicated by the induced
expression of the CD69 antigen, and their cytolytic activity
was strongly augmented by contact with LPS-treated mature
DCs or with immature DCs in the presence of the maturation
stimulus LPS [5].
We observed that DCs from tumor-bearing rats as well as
DCs previously activated with ¢xed AK-5 cells were able to
activate NK cells and render them cytolytic against NK-sen-
sitive target YAC-1 cells, whereas immature DCs were unable
to activate NK cells. DC maturation stimulus is very impor-
tant in activating NK cells. Moreover, when anti-IL-12 anti-
body was introduced in the DC-NK co-culture system, NK
cells signi¢cantly lost their cytolytic activity. Spent culture
medium from mature DCs alone was unable to activate NK
cells, suggesting that in addition to IL-12, cell^cell contact and
NK to DC ratios were crucial in achieving signi¢cant activa-
tion in NK cells.
So far, several methods using DCs to induce antitumor
immunity have been investigated: DCs pulsed with proteins
or peptides extracted from tumor cells [21^23], DCs trans-
fected with genes encoding tumor-associated antigens [24],
DCs cultured with tumor cells [25] and DCs fused with tumor
cells [26^29]. Evidence of clinical improvement such as regres-
sion of metastasis and enhanced T cell immunity, antigen-
speci¢c proliferative responses and delayed-type hypersensitiv-
ity reactions was observed in some cases, even in late stages of
the disease.
We adoptively transferred mature DCs isolated from 8th
day tumor-bearing rats into normal Wistar rats. These rats
also achieved activation of NK cells in vivo, and induced
signi¢cant cytotoxicity against YAC-1 cells in a 4 h 51Cr re-
lease assay (Fig. 5B). Adoptively transferred rats were chal-
lenged by transplanting a low dose of AK-5 tumor cells i.p.
(1U106 AK-5 cells/rat) and monitored for ascites develop-
ment and delay in mortality. Compared to normal rats, adop-
tively transferred rats showed slow progression in ascites for-
mation and delay in mortality. But we could not achieve
complete protection against AK-5 tumor challenge (data not
shown). This could be attributed to the rapid growth of tumor
cells in the peritoneum thereby not giving enough time for the
Fig. 5. A: Role of IL-12 secreted by DCs on NK cell activation.
IL-12 secreted by DCs was neutralized by anti-IL-12 antibody and
its e¡ect on NK cell cytotoxicity against YAC-1 was studied. In the
presence of anti-IL-12 mAb (10 Wg/ml), NK cell cytotoxicity was in-
hibited signi¢cantly. Controls were treated with isotype-matched
antibody. B: Adoptive transfer of mature DCs (from 8th day tu-
mor-bearing rats) to normal rats and its e¡ect on NK cell activa-
tion. NK cells from animals that had received activated DCs
showed signi¢cantly higher cytotoxic activity against YAC-1 cells as
compared to naive NK cells (nNK). adNK denotes NK cells ob-
tained from animals that were injected with activated DCs.
*P6 0.001 with respect to control.
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host immune system to mount an e¡ective anti-tumor re-
sponse. Alternatively, overexpression of CD95-L by day 3
and day 4 ascitic tumor cells may be involved in depleting
the peritoneum of CD95þ-activated lymphocytes [30].
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